Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
4 October 2016
E-007539-16
Question for written answer
to the Commission
Rule 130
Jiří Maštálka (GUE/NGL)

 Subject:  Access to medicines
 Answer(s) 

It is evident that the EU’s current biomedical R&D system based on IP monopolies has proved to be a failure when it comes to delivering accessible and affordable lifesaving medicines, and that the EU has not received a sufficient return on its public investment in biomedical R&D in terms of the ownership of research results.

1. How will the Commission amend the current system of IP monopolies in order to guarantee access to affordable medicines for all?

2. How will the Commission increase the transparency of research and development costs when EU funds are invested in the development of new medicines?

Last updated: 18 October 2016Legal notice